Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy
CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.
Is Zentalis Pharmaceuticals, Inc. on track for accelerated approval in ovarian cancer
Can azenosertib secure accelerated approval? Explore how Zentalis Pharmaceuticals, Inc.’s trials could reshape ovarian cancer treatment.
ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice
Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.
Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?
Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.
Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough?
Debiopharm’s ovarian cancer combo won FDA Fast Track after AACR 2026 data. Read what it means for DDR therapy, biomarkers, and clinical risk.
Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Zentalis Pharmaceuticals aligns DENALI and ASPENOVA trials with evolving ovarian cancer treatment landscape
Zentalis Pharmaceuticals advances azenosertib through DENALI and ASPENOVA. Read what this means for ovarian cancer strategy and approval risk.
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.
Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.